Yingsi Intelligence and Exelixis have reached a global exclusive licensing agreement
Recently, Yingsi Intelligence and global oncology biotechnology company Exelixis jointly announced that they have signed an exclusive licensing agreement. Exelixis will receive the global development and commercialization rights for Yingsi Intelligence's potential best in class anti-tumor innovative therapy ISM3091 project. Yingsi Intelligence will receive a prepayment of $80 million, based on milestone payments for project development, commercialization, and sales, as well as graded royalties for future product net sales.
ISM3091 is a potential best of its kind small molecule inhibitor that targets the synthetic lethal target USP1 of BRCA mutated tumors. It is developed by the AI platform independently developed by Yingsi Intelligence and has strong activity in tumor models with BRCA gene mutations. In April of this year, the US Food and Drug Administration approved a new drug clinical trial application from Yingsi Intelligence for conducting clinical trials of ISM3091 in a population of solid tumor patients.
Yingsi Intelligence, an artificial intelligence drug development company located in Pudong, is a clinical stage drug development company driven by generative artificial intelligence. It connects biology, chemistry, and clinical trial analysis through next-generation artificial intelligence systems, and uses modern machine learning technologies such as deep generative models, reinforcement learning, and transformation models to build a powerful and efficient artificial intelligence drug development platform. It identifies new targets and generates candidate drugs with specific molecular structures. Yingsi Intelligence focuses on unmet medical needs in areas such as cancer, fibrosis, immunity, central nervous system diseases, and age-related diseases, promoting and accelerating innovative drug research and development.
The reporter learned that ISM3091 is the third clinical stage project discovered by Yingsi Intelligence under the empowerment of the artificial intelligence generation platform Chemistry42. The novel structure, anti-tumor activity and excellent drug like properties of this compound make it a potential differentiation project for the treatment of BRCA mutation related cancers, such as breast cancer, ovarian cancer and prostate cancer.
Dr. Alex Zhaovoronkov, founder and CEO of Yingsi Intelligence, said, "Currently, we have a very wide range of anti-cancer drug combinations. When selecting cancer targets, we always seek a balance between novelty, credibility, and commercial operability." Currently, the company has 31 drug pipelines.
![Yingsi Intelligence and Exelixis have reached a global exclusive licensing agreement](https://a5qu.com/upload/images/2306fdb0c8b37d49c87176a4205d33aa.jpg)
Text: Yang Zhenying
*Reprinted from official WeChat account released by Pudong